🔓 For a limited time until October 25, we are offering free promotional access to a new article in
#CJC!
This study leverages the TriNetX research network to evaluate the clinical effectiveness of GLP 1 RAs in patients with diabetes or obesity undergoing TAVR.
• At 1 year follow up, GLP 1 RA use was associated with a lower risk of multiple cardiovascular outcomes, including MACE and all-cause mortality, compared with non users.
• These findings are hypothesis generating for GLP 1 RAs as adjunctive therapy, in addition to guideline directed medical therapy, in patients undergoing TAVR.
Read here ⬇️
onlinecjc.ca/article/S0828-2…